FANCI and FANCD2 have common as well as independent functions during the cellular replication stress response by Thompson, Elizabeth L. et al.
Published online 20 October 2017 Nucleic Acids Research, 2017, Vol. 45, No. 20 11837–11857
doi: 10.1093/nar/gkx847
FANCI and FANCD2 have common as well as
independent functions during the cellular replication
stress response
Elizabeth L. Thompson1,†, Jung E. Yeo1,2,†, Eun-A Lee2, Yinan Kan3, Maya Raghunandan2,
Constanze Wiek4, Helmut Hanenberg4,5, Orlando D. Scha¨rer2, Eric A. Hendrickson1 and
Alexandra Sobeck1,*
1Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455,
USA, 2Center for Genomic Integrity (CGI), Institute for Basic Science (IBS), Ulsan National Institute of Science and
Technology (UNIST), Ulsan 44919, South Korea, 3Department of Genetics, Harvard Medical School, 77 Avenue
Louis Pasteur, Boston, MA 02115, USA, 4Department of Otorhinolaryngology and Head/Neck Surgery,
Heinrich-Heine University, 40225 Du¨sseldorf, Germany and 5Department of Pediatrics III, University Children’s
Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany
Received January 26, 2017; Revised September 9, 2017; Editorial Decision September 12, 2017; Accepted September 16, 2017
ABSTRACT
Fanconi anemia (FA) is an inherited cancer predis-
position syndrome characterized by cellular hyper-
sensitivity to DNA interstrand crosslinks (ICLs). To
repair these lesions, the FA proteins act in a lin-
ear hierarchy: following ICL detection on chromatin,
the FA core complex monoubiquitinates and recruits
the central FANCI and FANCD2 proteins that sub-
sequently coordinate ICL removal and repair of the
ensuing DNA double-stranded break by homology-
dependent repair (HDR). FANCD2 also functions dur-
ing the replication stress response by mediating
the restart of temporarily stalled replication forks
thereby suppressing the firing of new replication ori-
gins. To address if FANCI is also involved in these
FANCD2-dependent mechanisms, we generated iso-
genic FANCI-, FANCD2- and FANCI:FANCD2 double-
null cells. We show that FANCI and FANCD2 are par-
tially independent regarding their protein stability,
nuclear localization and chromatin recruitment and
contribute independently to cellular proliferation. Si-
multaneously, FANCD2––but not FANCI––plays a ma-
jor role in HDR-mediated replication restart and in
suppressing new origin firing. Consistent with this
observation, deficiencies in HDR-mediated DNA DSB
repair can be overcome by stabilizing RAD51 fila-
ment formation in cells lacking functional FANCD2.
We propose that FANCI and FANCD2 have partially
non-overlapping and possibly even opposing roles
during the replication stress response.
INTRODUCTION
FA (Fanconi anemia) is an inherited genomic instability
disorder that is characterized by bone marrow failure and
a strong predisposition to cancer, predominantly leukemia
and squamous cell carcinoma (1,2). A defining character-
istic of FA patient cells is that they are highly sensitive to
DNA ICL (interstrand crosslink)-inducing agents such as
MMC (mitomycin C) and DEB (diepoxybutane). More-
over, FA cells exhibit spontaneous chromosomal aberra-
tions that are further exacerbated upon treatment with
replication inhibiting agents such as HU (hydroxyurea) or
APH (aphidicolin) (1,3,4). Thus, the FA pathway consti-
tutes an extremely important pathway for the maintenance
of genome stability. Currently, 21 different FA genes have
been identified and mutations in any one of them are suffi-
cient to cause FA (5–7).
The canonical FA pathway of DNA ICL repair is
thought to consist of three layers: an upstream FA core
complex (8 proteins), a central protein heterodimer com-
posed of FANCI and FANCD2 (the ID2 complex),
and a growing number of downstream proteins includ-
ing FANCD1/BRCA2 (breast cancer associated protein 2)
and the FANCR/RAD51 (radiation sensitive 51) recom-
binase (5,8). Repair of the DNA ICLs occurs predomi-
nately in S-phase when they block the progression of repli-
cation forks (9,10). Following DNA ICL detection during
S-phase, the FA core complex acts as an E3 ubiquitin lig-
ase that monoubiquitinates FANCI and FANCD2, facili-
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tating their recruitment to DNA ICLs on chromatin (11–
14). Subsequently, the chromatin-bound ID2 complex co-
ordinates downstream FA scaffolding proteins and nucle-
ases like FANCP/SLX4 (synthetically lethal in the absence
(X) of Sgs1 4) and FANCQ(XPF)/ERCC1 (xeroderma
pigmentosum F/excision repair cross-complementing 1), re-
spectively, along with BRCA2 and RAD51 to mediate in-
cisions at the DNA ICL, followed by HDR (homology-
dependent repair) of the newly generated DNA DSBs
(double-stranded breaks) (5,8,15–20).
Recent studies from our laboratory and others discov-
ered novel roles for FANCD2 during the replication stress
response (4,21–26). Upon replication fork stalling in the
presence of HU or APH, FANCD2 is recruited to the
stalled forks where it performs dual roles. First, it protects
the stalled replication forks from nucleolytic degradation
(4,21). FANCD2 fulfills this role in concert with the up-
stream FA core complex and several downstream FA pro-
teins such as BRCA2 andRAD51 (4,26). Second, FANCD2
promotes restart of the stalled replication forks while block-
ing the firing of new replication origins (22,24,25). Interest-
ingly, the fork restart function of FANCD2does not depend
on the FA core complex nor on FANCD2 monoubiquiti-
nation (25). Instead, the non-ubiquitinated FANCD2 iso-
form binds chromatin upon replication fork stalling and co-
operates with downstream FA factors such as BRCA2 and
FANCJ (25) as well as non-FA DNA repair proteins such
as the BLM (Bloom syndrome) helicase complex (22), CtIP
(C-terminal interacting protein) (24) and FAN1 (Fanconi-
associated nuclease 1) (23) to promote fork restart. Intrigu-
ingly, previous findings from our laboratory suggested that
FANCD2 may fulfill some of its roles during the cellular
replication stress response independently of FANCI. Using
the Xenopus laevis S-phase extract system, we showed that
FANCD2 dissociates from FANCI upon replication stress
and is recruited to chromatin prior to FANCI (27). More-
over, FANCD2 participates in the assembly of the BLM
complex independently of FANCI (22). However, if and
howFANCI contributes tomechanisms of replication stress
recovery is not well understood.
To dissect the roles of FANCI and FANCD2 during the
replication stress response, we generated humanFANCI−/−,
FANCD2−/− and FANCI−/−:FANCD2−/− knockout cells
in an isogenic background (the HCT116 cell line). Analysis
of these cells revealed that FANCI andFANCD2 act in con-
cert to promote DNA ICL repair, but have partially inde-
pendent roles during the HU- or APH-triggered replication
stress response. Our findings indicate that FANCD2 fulfills
crucial roles in mediating cellular resistance to HU or APH
independent of FANCI. In fact, HU- or APH-triggered cell
death in FANCD2-deficient cells was FANCI-dependent,
suggesting opposing roles of FANCD2 and FANCI dur-
ing cell survival. Moreover, FANCD2 played a significantly
more important role during the HDR-mediated, RAD51-
dependentmechanisms of replication fork restart andDNA
DSB repair. Our results suggest that whereas FANCD2 sup-
ports cellular survival and fork recovery in the face of APH-
or HU-triggered replication stress, FANCI may in fact op-
pose those functions.
MATERIALS AND METHODS
Generation of FANCI-null (I−/−) and FANCD2-null
(D2−/−) cells using rAAV-mediated gene targeting
FANCI-null and FANCD2-null HCT116 cells were gen-
erated using rAAV (recombinant adeno-associated virus)-
mediated gene targeting (28). Conditional and knock-out
rAAV vectors targeting FANCI exon 10 and FANCD2 exon
12 were constructed using Golden Gate cloning and de-
signed as described (28–30). We targeted FANCD2 exon 12
and FANCI exon 10 since these exons both lie within re-
gions encoding conserved protein domains associated with
heterodimer formation and putative DNA binding (31–33),
and the deletion of these exons should result in frameshift
mutations. The first round of targeting with a conditional
vector replaced FANCI exon 10 and FANCD2 exon 12
with their respective conditional, floxed (flanked by LoxP
sites) alleles along with an NEO (neomycin) selection cas-
sette, also flanked by LoxP sites. G418-resistant clones were
screened by polymerase chain reaction (PCR) to confirm
correct targeting, and Cre (cyclization recombinase) tran-
siently expressed from an adenoviral vector (hereafter Ad-
Cre) was then used to remove theNEO selection cassette as
described (28–30). Retention of the FANCI floxed exon 10
and FANCD2 floxed exon 12 in the conditional allele was
confirmed by PCR. The second round of FANCD2 gene
targeting was performed in the FANCD2flox/+ cells with a
knock-out rAAV vector in which exon 12 was replaced with
an NEO selection cassette. The second round of FANCI
gene targeting was performed in the FANCIflox/+ cells us-
ing the same conditional vector that had been used in the
first round of targeting.G418-resistant clones were screened
by PCR for correct targeting. Primer sequences for all PCR
reactions are listed in Supplementary Table S1. AdCre re-
combinase was then used to remove both the NEO selec-
tion cassette and the conditional allele(s) and resulted in vi-
able I−/− and D2−/− clones. Two independent I−/− clones
(labeled as clones #28 and #30) and a single D2−/− clone
(labeled as clone #39) were generated. These three clones
and the clones described below were used interchangeably
for most of the subsequent experiments.
CRISPR/Cas9 generation of FANCD2−/− and
FANCI−/−:FANCD2−/− (ID2 DKO) cells
A guide RNA (gRNA) targeting FANCD2 exon 11 was
designed so that Cas9 (CRISPR associated 9) cleavage
would disrupt an endogenous restriction enzyme recogni-
tion site for BpuEI. The gRNA was cloned into a CRISPR
(clustered regularly interspersed short palindromic
repeats)/Cas9 plasmid (hSpCas9–2A-Puro/px459) as de-
scribed (34). WT (wild-type) HCT116 cells were transfected
with the CRISPR/Cas9 plasmid containing the gRNA
targeting FANCD2 exon 11 using Lipofectamine 3000
(Life Technologies). Two days after transfection, the cells
were subcloned, and individual subclones were screened
for targeting by PCR amplification of exon 11 and by
subsequent digestion with the restriction enzyme BpuEI
(New England BioLabs, Inc.). Clones that were resistant to
digestion with BpuEI were TOPO TA cloned (Life Tech-
nologies). Sequencing of the TOPO TA clones confirmed
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targeted bi-allelic disruption that induced frameshifts in
FANCD2, generating an independent FANCD2-null cell
line, designated as clone #29 (Supplementary Figure S1A).
In a highly similar fashion FANCI-null cells were also
transfected with the CRISPR/Cas9 plasmid containing the
gRNA targeting FANCD2 exon 11 using Lipofectamine
3000 (Life Technologies). Subsequent sequencing of the re-
sulting TOPO TA clones confirmed targeted bi-allelic dis-
ruption that induced frameshifts in FANCD2, generating
two independent ID2 DKO (double knockout) cell lines,
which were arbitrarily designated as clone #1 and clone #2.
Western blot analysis further confirmed that these clones
were null for FANCD2 and FANCI expression. Primer se-
quences for all PCR reactions are listed in Supplementary
Table S1.
To demonstrate unequivocally that the reagents (rAAV
or CRISPR/Cas9) were irrelevant to the resulting pheno-
types of the cell lines used in these experiments we also
generated additional ID2 DKO clones (arbitrarily desig-
nated as clones #3 and #4). These clones were created start-
ing with D2−/− clone #29 (CRISPR/Cas9 generated) and
D2−/− clone #39 (rAAV generated) cell lines, respectively.
A gRNA targeting FANCI exon 9 was designed so that
Cas9 cutting would disrupt an endogenous restriction en-
zyme recognition site for AcuI. The gRNA was cloned into
a CRISPR/Cas9 plasmid (hSpCas9(BB)-2A-GFP/ PX458;
Addgene plasmid #48138). This CRISPR/Cas9 plasmid
co-expresses Cas9 and GFP, and therefore GFP-expressing
cells were collected two days after transfection by flow cy-
tometry and subcloned. Subclones were screened for cor-
rect targeting by PCR amplification of FANCI exon 9 and
subsequent digestion with AcuI (New England BioLabs,
Inc.). Clones that were resistant to digestion with AcuI were
TOPO TA cloned and ID2−/- clones #3 and #4 were se-
quence confirmed for biallelic frameshift-inducing muta-
tions (Supplementary Figures S1B and C). Additionally,
western blot analyses confirmed that these cell lines did
not express any WT FANCI or FANCD2 protein nor was
there any evidence of expression of potential truncated pro-
tein products (Supplementary Figures S1D and E). In toto,
these experiments demonstrated that the cells were func-
tional DKOs. DKO clones #3 and #4 were used exclusively
in the experiments in which growth of the cell lines was as-
sessed (Figure 4A).
Complementation of D2−/− and I−/− cells
For expression of hFANCD2, the human FANCD2 tran-
script 1 cDNA (NM 001018115) was optimized by silent
mutagenesis, thereby introducing unique restriction enzyme
recognition sites and removing potential prokaryotic insta-
bility motifs, cryptic splice sites, RNA instability motifs and
polyA sites (Hanenberg et al., in preparation). The cDNA
was purchased fromGenScript (Piscataway, NJ, USA). The
D2−/− cells were complemented using the optimized hu-
man FANCD2 expression cassette that wasGateway-cloned
into a PiggyBac transposase vector containing a CAG
(cytomegaloviral/beta-actin/beta-globin) promoter and an
NEO selection cassette.G418-resistant cloneswere screened
for FANCD2 expression by western blot analyses.
The I−/− cells were complemented by performing a
third round of gene targeting to ‘knock back in’ a
functional FANCI allele. This was accomplished using a
CRISPR/Cas9 gRNA designed to target immediately 5′ of
the LoxP scar left when exon 10 was removed to create the
I−/− cells. The FANCI conditional rAAV plasmid contain-
ing the FANCI exon 10 flanked by LoxP sites and an NEO
selection cassette, also flanked by LoxP sites was used as
the donor template. G418-resistant clones were screened for
the knock-in of FANCI exon 10, and PCR was used to con-
firm heterozygous knock-in in two clones. The NEO selec-
tion cassette was subsequently removed by transient treat-
ment with AdCre recombinase, and retention of FANCI
exon 10 was confirmed by PCR and DNA sequencing. Re-
stored FANCI expression from the knock-in floxed allele
was confirmed by Western blot analyses. Throughout the
manuscript, the complemented cell lines are designated as
(D2−/−:D2, I−/−:I) for D2- and I-null, cells respectively.
Finally, I−/− cells overexpressing FANCD2 protein were
established by introducing a PiggyBac transposon contain-
ing the FANCD2 codon-optimized cDNA described above
into I−/− cells (clone #28). Two FANCD2-overexpressing
FANCI-null cell lines (named clones #2 and #12) were iden-
tified byWestern blot analysis. These clones were designated
as I−/−:D2o/e.
Cell proliferation assay
WT cells, knockout cells and complemented cells were
plated in 6-well tissue culture plates according to their
plating efficiency: WT cells were plated at 2500 cells/well,
complemented cells (D2−/−:D2, I−/−:I) were plated at 5000
cells/well and the D2−/−, I−/− and ID2 DKO cells were
plated at 6000 cells/well. Cell counts were performed in trip-
licate 4, 6 or 8 days after seeding.
MMC sensitivity assay
Cells were plated in triplicate in 96-well plates accord-
ing to their plating efficiency. WT cells were plated at
750 cells/well, complemented cells (D2−/−:D2, I−/−:I) were
plated at 1000 cells/well and theD2−/−, I−/− and ID2DKO
were plated at 1200 cells/well. On the following day, the
media was removed and replaced with media containing
0, 5, 10 or 15 nM MMC. Cells were allowed to grow for
5 days and cell viability was measured with CellTiter96
Aqueous (Promega) according to the manufacturer’s in-
structions. The viability of MMC-treated cells was normal-
ized to the average viability of the untreated control cells for
each cell line.
Cell cycle analysis
WT cells, knockout cells and complemented cells were
plated in 6-well plates according to their plating efficiency.
WT cells were plated at 100 000 cells/well, singly-null and
complemented cells were plated at 200 000 cells/well and
DKO cells were plated at 32 000 cells/well. After 24 h,
the media was removed and either untreated media, me-
dia containing 100 nM APH or media containing 10 nM
MMC was added to the cells. After 24 h the cells were
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harvested and fixed with 1% paraformaldehyde and sub-
sequently with cold 70% ethanol. Fixed cells were washed
with PBS (phosphate-buffered saline), stained (with PBS
containing 40 g/ml propidium iodide; 100 g/ml RNase
A) andRNase treated (37◦C for 30min). Samples were then
filtered through a cell strainer cap (Corning) and sorted on a
BD Accuri C6 instrument and analyzed using FlowJo soft-
ware (V10.1).
Colony forming assay
WTcells, null cells and complemented cells were plated in 6-
well plates in triplicate according to their plating efficiency.
WT cells were plated at 300 cells/well, complemented cells
(D2−/−:D2, I−/−:I) were plated at 400 cells/well, I−/− cells
were plated at 600 cells/well andD2−/− and ID2DKO cells
were plated at 800 to 1000 cells/well. After 24 h, the media
was removed and dimethyl sulfide (DMSO) media or media
containing 0, 50 100 or 150 M HU, or media containing
0, 10, 25 or 50 nM APH was added in triplicate. Cells were
incubated for 12 to 14 days, washed in PBS, fixed in 10%
acetic acid/10% methanol and stained with Coomassie as
described (35). Colonies reaching aminimum size of 50 cells
were counted and normalized to the average colony number
in untreated wells.
DNA repair assays
The HDR reporter assay was performed with the DR-GFP
plasmid as described (36). The DR-GFP reporter plasmid
contains two mutated GFP genes in tandem, and one of the
mutated GFP genes contains an I-SceI restriction enzyme
recognition site. If HDR/gene conversion between the two
mutated GFP genes is used to repair the DSB induced by
I-SceI digestion, then GFP expression is restored.
The A-NHEJ (alternative non-homologous end joining)
reporter assay was performed with the pEJ2-GFP plas-
mid as described (30,37). The pEJ2-GFP reporter plasmid
contains a GFP expression cassette interrupted by an I-
SceI restriction enzyme site and three stop codons flanked
by 8 bp of microhomology. If microhomology-mediated
repair (i.e. A-NHEJ) is used to repair the DSB induced
by I-SceI restriction enzyme digestion, then GFP expres-
sion is restored. For both DNA repair assays, three plas-
mids including the reporter plasmid (DR-GFP or pEJ2-
GFP), an I-SceI expression plasmid, and a mCherry ex-
pression plasmid (which was used as a transfection con-
trol) were co-transfected into the cells using Lipofectamine
3000 (Life Technologies). Seventy-two hours after transfec-
tion, the cells were fixed with 4% paraformaldehyde and
sorted by FACS (fluorescence-activated cell sorting). The
DNA repair efficiencies were determined as the number of
dual GFP-positive and mCherry-positive cells divided by
the number of mCherry-positive cells. The values were nor-
malized to the repair efficiency observed in WT cells. For
the RS-1 treatment during the HDR assay, 7.5 nM RS-1
was added to the media 2 h prior to plasmid transfection.
Fresh media containing 7.5 nM RS-1 was added again 24 h
after transfection.
Preparation of whole cell extracts (WCE), as well as nuclear
and chromatin fractions
For WCE (whole cell extract) preparation, cells were
washed in PBS, resuspended in lysis buffer (10 mM Tris pH
7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
1 mM ethylenediaminetetraacetic acid, 1 mMdithiothreitol
(DTT), 0.5 mg/ml pefabloc protease inhibitor) and incu-
bated on ice for 20 min. Cell extracts were centrifuged for 5
min at 10 000 rpm, and the supernatant was used for further
analysis. Nuclear and chromatin fractions were prepared
using a Subcellular Protein Fractionation Kit (Thermo Sci-
entific).
Antibodies
The following antibodies were used for western blot-
ting and immunofluorescence assays: anti-FANCD2 (Santa
Cruz, sc-20022 and Abcam, ab2187), anti-FANCI (Bethyl
Laboratories, A300–212), anti-FANCI (38), anti-Ku86
(Santa-Cruz, sc-5280), anti-CtIP (39), anti-RAD51 (Santa
Cruz sc-8349), anti-GAPDH (Genetex, GTX627408), anti-
tubulin (Abcam, ab7291), anti- -H2AX (Bethyl Laborato-
ries, A300–081), anti-phospho-p53 (Ser15) (Santa Cruz, sc-
11764-R), anti-p21 (Santa Cruz, sc-397) and anti-PCNA
(Calbiochem, PC10).
Immunoblotting
Protein samples were separated on gradient gels and
transferred to Immobilon P membranes (Millipore). Af-
ter blocking in 5% milk, the membranes were incubated
with the following primary antibodies: FANCD2 (1:1000),
FANCI (1:2000), Ku86 (1:5000), GAPDH (1:5000), CtIP
(1:400), PCNA (1:5000),  -H2AX (1:10,000), phospho-
p53 (1:1,000) and p21 (1:400). A horseradish peroxidase-
conjugated rabbit secondary antibody (Jackson Laborato-
ries) or a mouse secondary antibody (Biorad) were used at
dilutions of 1:10 000 and 1:3000, respectively. Protein bands
were visualized using an EL Plus system (Amersham).
Immunofluorescence analysis of DNA repair foci
Indirect immunofluorescence was carried out essentially
as described (40). The primary antibodies used were:
FANCD2 (Abcam, ab2187, 1:4000), CtIP (mouse mono-
clonal, 1:400) and RAD51 (Calbiochem, PC130, 1:1000).
The secondary antibodies used were: Alexa Fluor 594-
conjugated goat anti-rabbit (1:1000) and Alexa Fluor 488-
conjugated goat anti-mouse (1:1000; Molecular Probes).
For statistical analysis of nuclear foci formation, images
were taken using a Leica DM LB2 microscope with a
Hamamatsu Orca-ER camera. Quantification of CtIP and
RAD51 foci was carried out using ImageJ.
DNA fiber assay
We used a vetted DNA fiber protocol (41). Moving repli-
cation forks were labeled with DigU (digoxigenin-dUTPs)
for 25 min and then with BioU (biotin-dUTPs) for 40
min. To allow efficient incorporation of the dUTPs, a hy-
potonic buffer treatment (10 mM HEPES, 30 mM KCl,
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pH 7.4) preceded each dUTP-labeling step. To visual-
ize labeled fibers, cells were mixed with a 10-fold ex-
cess of unlabeled cells, fixed and dropped onto slides.
After cell lysis, DNA fibers were released and extended
by tilting the slides. Incorporated dUTPs were visualized
by immunofluorescence detection using anti-digoxigenin-
Rhodamine (Roche) and streptavidin-Alexa-Fluor-488 (In-
vitrogen). Images were captured using a Deltavision micro-
scope (Applied Precision) and analyzed using Deltavision
softWoRx 5.5 software. All DNAfiber results shown are the
means of two or three independent experiments (using 300
DNA fibers/experiment). Error bars represent the standard
error of the mean (SEMS) and the significance was deter-
mined by t-test and Mann–Whitney tests. Statistical signif-
icance at P< 0.05, P< 0.01 and P< 0.001 are indicated as
*, **, ***, respectively.
Molecular DNA combing assay
We carried out DNA combing assays (42) as described in
the manufacturer’s protocol (Genomic Vision), with some
modifications as described below. Briefly, moving repli-
cation forks were labeled with 5-chloro-20-deoxyuridine
(CldU, Sigma-Aldrich) for 20 min and then with 5-iodo-20-
deoxyuridine (IdU, Sigma-Aldrich) for 40 min. To achieve
lysis, the cells were embedded in low-melting agarose (Bio-
Rad) followed by incubation in DNA extraction buffer
(0.5MMES buffer, pH 5.5, Millipore). To stretch the DNA
fibers, silanized coverslips (22 × 22 mm, Genomic Vision)
were dipped into the extracted DNA buffer for 13 min and
then pulled out a constant speed at 300 um/s. The cover-
slips were then baked at 60◦C for 4 h and incubated with
2.5 M HCl for denaturation. Incorporated CldU and IdU
were visualized using a rat anti-BrdU antibody (dilution
1:50 ∼ 1:100 for CldU, Abcam) or a mouse anti-BrdU anti-
body (1:10 ∼ 1:50 for IdU, Becton Dickinson). Slides were
fixed with 4% paraformaldehyde in PBS and incubated with
Alexa Fluor 488-conjugated goat anti-rat antibody (dilu-
tion 1:100 ∼ 1:200, Molecular Probes/Thermo Fisher) or
Alexa Fluor 568-conjugated goat anti-mouse antibody (di-
lution 1:100 to 1:200, Molecular Probes/Thermo Fisher)
for 1 h. Finally, coverslips were mounted with ProLong
Gold Antifade Reagent (Molecular Probes) and stored at
−20◦C.DNAfiber imageswere captured using LSM880mi-
croscope (Carl Zeiss).
All DNA combing results shown are the means of
two or three independent experiments (using 300 DNA
fibers/experiment). Error bars represent the standard error
of themean (SEMS) and the significance was determined by
a t-test. Statistical significance at P< 0.05, P< 0.01, and P
< 0.001 are indicated as *, **, ***, respectively.
Statistical analysis
Error bars represent the standard deviation of themean and
P-values were determined using a Student’s t-test. Statisti-
cal significances at P < 0.05, P < 0.01 and P < 0.001 were
indicated as *, ** and ***, respectively. A summary of allP-
values for results shown in Figures 3–6 is provided in Sup-
plementary Table S2.
RESULTS
Generation and complementation of human FANCI,
FANCD2 and FANCI:FANCD2 DKO knockout cell lines
To knock out the FANCD2 and FANCI genes in the
parental HCT116 cell line, a conditional knockout ap-
proach was used. We chose this approach since all patient-
derived cells from complementation groups FA-D2 and FA-
I described to date exhibit residual expression of FANCD2
(43) or FANCI (12,44,45), respectively, which raised the
possibility that FANCD2 and/or FANCImight be essential
in human somatic cells. The conditionally null cell lines were
created using recombinant adeno-associated virus (rAAV)
gene targeting techniques, as described (Figure 1) (28–
30,46). Thus, the FANCD2−/− cell line (D2−/− clone #39)
was generated using two rounds of rAAV gene targeting,
first with the conditional vector (Figure 1A) and second
with the knockout vector (Figure 1B). To unequivocally
demonstrate that the technology utilized to generate the
knockout cell lines was irrelevant to the cell’s subsequent
phenotypes we also generated (described in the ‘Materials
and Methods’ section) a second FANCD2 knockout clone
(D2−/− clone #29) utilizing CRISPR/Cas9 technology.
Similarly, the FANCI−/− cell lines (I−/−) were generated
using two rounds of targeting with a conditional rAAV vec-
tor (Figure 1A). In this fashion, two independent FANCI-
null clones were obtained and designated as clone #28 and
clone #30, respectively. These experiments demonstrated
that our original concern about the possibility of these genes
being essential was unwarranted as null cell lines corre-
sponding to both genes were readily isolated.
Deletion of the targeted exons was confirmed by PCR
amplification across the deleted exon region resulting in sig-
nificantly smaller PCR products for the null alleles (Fig-
ure 2A). Since the FANCD2 exon 12 was targeted with
two different rAAV vectors that were designed to gen-
erate different-sized deletions the D2−/− genotype could
consequently be confirmed by the appearance of the two
differently-sized PCR products (‘Null’ bands of 365 and
151 bp; Figure 2A). Confirmation of the I−/− genotype was
achieved by PCR amplification across FANCI exon 10 re-
sulting in a single PCR band representing deletion of exon
10 on both alleles (‘Null’ band of 252 bp; Figure 2A).
To generate the FANCD2−/−:FANCI−/− doubly-null cell
line (ID2 DKO), we utilized CRISPR/Cas9 gene target-
ing to knock out FANCD2 in the I−/− cell line (Figure
2B–D). A guide RNA was designed to target the Cas9 en-
donuclease to cleave within an endogenous restriction en-
zyme recognition site (BpuEI) in FANCD2 exon 11. Subse-
quently, mutagenic insertion or deletions (indels) created by
end joining repair of the CRISPR/Cas9-mediated DSB in
FANCD2 were detected by disruption of the BpuEI restric-
tion enzyme site (Figure 2B). Screening of targeted clones
revealed two independent clones with complete resistance
to digestion with BpuEI, indicating bi-allelic disruption of
FANCD2 in the I−/− cells (Figure 2C). Sequence analysis
of the targeted region was used to confirm that both clones
had CRISPR/Cas9-induced bi-allelic frameshift mutations
in FANCD2, resulting in two independent viable ID2DKO
cell lines (Figure 2D; arbitrarily designated as clones #1
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Figure 1. rAAV-mediated generation ofFANCD2−/− (D2−/−),FANCI−/−
(I−/−) and FANCI−/−:FANCD2−/- (ID2 DKO) cell lines. (A) Schematic
of FANCD2 (left panel) and FANCI (right panel) targeting strategies in
HCT116 cells. FANCD2 exon 12 and FANCI exon 10 were targeted for
deletion by rAAV gene targeting. The first allele targeting was performed
using conditional rAAV vectors for FANCD2 and FANCI. The conditional
vectors contain rAAV inverted terminal repeats (ITRs) (gray boxes), ho-
mology arms (white boxes), an NEO selection cassette (green boxes) and
the targeted exon (blue boxes) flanked by LoxP sites (orange triangles).
Targeted clones were treated with Cre recombinase to remove the NEO
selection cassette. (B) The second allele targeting was performed in the
FANCD2flox/+ cell line (f/+) using a FANCD2 knockout rAAV vector and
in the FANCIflox/+ cell line (f/+) with the same FANCI conditional rAAV
vector utilized in the first round of targeting. Targeted clones were treated
with Cre recombinase to remove both the NEO selection cassette and
the conditionally floxed exons, resulting in the generation of FANCD2−/−
(D2−/−) and FANCI−/− (I−/−) cell lines.
and #2, respectively). To once again demonstrate that the
knockout technology used to construct the cell lines was ir-
relevant to their biological phenotypes, we also generated
(described in the ‘Materials and Methods’ section) two ad-
ditional ID2 DKO clones in a converse fashion to that de-
scribed above, thus inactivating FANCI in a FANCD2-null
cell line. These clones were arbitrarily designated as ID2
DKO clones #3 and #4, respectively.
Western blot analysis ofWCEprepared fromWT,D2−/−,
I−/− and ID2 DKO cells confirmed that the genetically-
null cells lacked expression of FANCD2, FANCI or both
proteins, respectively, compared to the WT cells (Figure
3A and B; Supplementary Figure S1D and E). Comple-
mentation of the D2−/− cell line (D2−/−:D2) was accom-
plished by stable genome integration of a constitutively ex-
pressed, sequence-optimized FANCD2 cDNA via a Pig-
gyBac transposon vector. Interestingly, we were unable to
follow this complementation strategy in I−/− cells, since
these cells did not maintain stable FANCI protein expres-
sion of a constitutively expressed FANCI cDNA (regardless
of whether the expression vector was a transposon, retro-
virus or plasmid; data not shown), similar to previous re-
ports (45,47). Instead, complementation of the I−/− cell
line was accomplished by a third round of CRISPR/Cas9-
mediated knock-in of the conditional exon 10 allele, result-
ing in reversion of theFANCI−/− genotype to aFANCIflox/−
genotype (designated as I−/−:I). Western blot analysis of the
complemented cell lines showed that the D2−/−:D2 and I−/−:I
cells exhibitedWT-like protein expression of FANCD2 and
FANCI, respectively (Figure 3Aand B). In agreement with
previous reports that FANCD2 and FANCI are interde-
pendent for their DNA damage-inducible monoubiquiti-
nation (12,27,44,48), HU treatment triggered FANCD2Ub
and FANCIUb formation in WT cells, but not in I−/− or
D2−/−cells, respectively (Figure 3A and B). Importantly,
FANCD2Ub and FANCIUb formation was fully restored in
D2−/−:D2 and I−/−:I cells (Figure 3A and B), demonstrating
a functional restoration of the key monoubiquitination step
in both complemented cell lines.
FANCD2 and FANCI are partially independent for their pro-
tein stability, nuclear import and chromatin recruitment and
contribute separately to normal cell proliferation
Several previous studies suggested that the FANCD2 and
FANCI proteins stabilize one another, while other reports
did not (12,27,44,48). To address this question, we com-
pared the expression levels of FANCD2 and FANCI inWT,
I−/− or D2−/− cells that were untreated or treated with 2
mM HU. FANCD2 protein levels in WCEs were reduced
by ∼50% in I−/− cells compared to WT cells regardless of
the absence or presence of HU-induced DNA damage (Fig-
ure 3C). Similarly, FANCI protein levels were reduced by
∼60% in untreated or HU-treatedD2−/− cells compared to
WT cells (Figure 3C). Thus, approximately half of the cellu-
lar FANCD2 and FANCI protein levels remain unaffected
in the absence of the respective binding partner.
FANCD2 and FANCI each contain nuclear localization
signals and can bind chromatin constitutively; moreover
their chromatin binding increases after replication stress
induction (12,27,49–51). To determine if FANCD2 and
FANCI rely on each other for their nuclear import, we an-
alyzed nuclear extracts from WT, D2−/− or I−/− cells that
were untreated or HU-treated for 6 or 24 h. In untreated
conditions, D2−/− and I−/− cells contained nuclear protein
levels of FANCI and FANCD2, respectively, that were com-
parable to those in WT cells (Figure 3D, compare lanes 1–
3). In contrast, while HU treatment stimulated a strong in-
crease in nuclear FANCD2 and FANCI protein levels in the
WT cells (Figure 3D, lanes 1, 4 and 7), no such increase was
observed in I−/− cells (Figure 3D, lanes 6 and 9) or D2−/−
cells (Figure 3D, lanes 5 and 8). These results suggest that
nuclear accumulation of FANCD2 and FANCI occurs in-
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Figure 2. Confirmation of D2−/−, I−/− and ID2 DKO cell lines. (A) PCR genotyping of D2−/− and I−/− cells and targeting intermediates. Left panel:
analyses of DNA fragments forWT (lane 1),D2flox/Neo (lanes 2 and 3) andD2−/− (lanes 4 and 5) after PCR amplification with primers FANCD2 EX11SF
and FANCD2 LoxPSR flanking the targeted exon. Right panel: analyses of DNA fragments after PCR amplification from WT (lane 1), Iflox/+ (lane 2)
and I−/− (lanes 3 and 4) cells using primers FancIc GG LIF and FancIcond GG LoxR flanking the targeted exon. The PCR amplification spanning the
targeted exons (exon 12 in FANCD2; exon 10 in FANCI) was used to confirm the removal of the respective exon in the D2−/− and I−/− cell lines. M: 1
kb markers. (B) Schematic of the FANCD2 targeting strategy in I−/− cells. CRISPR/Cas9-mediated gene targeting was used to functionally inactivate
FANCD2 in the I−/− cell line. A guide RNA (purple sequence) was designed targeting FANCD2 exon 11 with the Cas9 cut site (red arrow) overlapping an
endogenous BpuEI restriction enzyme recognition site (black bar). The PAM sequence of the sgRNA is shown in blue. Indels introduced at the Cas9 cut site
should disrupt the BpuEI cleavage site. (C) Genotyping of ID2 DKO cells. PCR amplification and BpuEI restriction enzyme digestion of FANCD2 exon
11 in WT, I−/− and two ID2−/− clones (1 and 2). Analyses of DNA fragments after PCR amplification with primers FancD2 CC F2 and FancD2 CC
R2 (blue arrows from panel B) fromWT (lanes 1 and 2), I−/− (lanes 3 and 4) and ID2DKO cells (lanes 5, 6, 7 and 8) that had been untreated (lanes 1, 3, 5
and 7) or treated with BpuEI (lanes 2, 4, 6 and 8). Cleavage by BpuEI produces two faster migrating fragments (D, lanes 2 and 4). Resistance (R) to BpuEI
digestion is seen in lanes 6 and 8 with the two ID2 DKO clones. (D) Sequence confirmation of CRISPR/Cas9 induced bi-allelic frameshift mutations in
FANCD2 in the two ID2 DKO clones #1 and #2.
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Figure 3. Initial characterization of the I−/−, I−/−:I, D2−/−, D2−/-:D2 and ID2 DKO cell lines. FANCD2 and FANCI are completely interdependent for
their replication stress-triggered monoubiquitination. (A) WCE was prepared from WT cells (lanes 1 and 2), D2−/− cells (lanes 3 and 4) or D2−/-:D2 cells
(lanes 5 and 6) that had been untreated (lanes 1, 3 and 5) or treated with 2 mM HU for 20 h (lanes 2, 4 and 6) and analyzed for the presence of FANCD2
and FANCI by western blot analysis. Ku86 was used as a loading control. (B) WCE were prepared from WT cells (lanes 1 and 2), I−/− cells (lanes 3 and
4), I−/−:I (clone 7) cells (lanes 5 and 6), I−/−:I (clone 11) cells (lanes 7 and 8) and ID2 DKO cells (lanes 9 and 10) that were untreated (lanes 1, 3, 5, 7 and
9) or treated with 2 mM HU for 20 h (lanes 2, 4, 6, 8 and 10) and analyzed for the presence of FANCD2 and FANCI by western blot analysis. Ku86 was
used as a loading control. (C) FANCD2 and FANCI are partially stable in the absence of one another. Left panel: WCE were prepared fromWT (lanes 1,
4 and 7), D2−/− (lanes 2, 5 and 8) and I−/− (lanes 3, 6 and 9) cells that were untreated (lanes 1–3) or treated with 2 mMHU for 6 h (lanes 4–6) or for 20 h
(lanes 7–9) and analyzed for FANCD2 and FANCI expression by western blot analysis. Tubulin was used as a loading control. Right panel: Immunoblot
signals shown in the left panel were analyzed by densitometry and normalized against the tubulin signals using ImageJ software. The graph shows the
percentage of FANCD2 and FANCI protein levels in I−/− and D2−/- cells, respectively, compared to the WT cells. (D) Nuclear import of FANCD2 and
FANCI becomes interdependent during replication stress. Nuclear fractions were isolated fromWT, D2−/− and I−/− cells that were untreated (lanes 1–3)
or HU-treated (lanes 4–9) for the indicated time points and analyzed for the presence of FANCD2 and FANCI. Ku86 was used as a loading control. (E)
Non-ubiquitinated FANCD2 binds chromatin independently of FANCI during normal replication and following replication stress. Chromatin fractions
were isolated from WT, D2−/− and I−/− cells that were untreated (lanes 1–3) or HU-treated (lanes 4–9) for the indicated time points and analyzed for the
presence of FANCD2 and FANCI. Ku86 was used as a loading control.
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dependently in unperturbed conditions, but becomes inter-
dependent during replication stress.
To determine the extent to which FANCD2 and FANCI
chromatin recruitment occurs interdependently, we pre-
pared chromatin factions from WT, D2−/− or I−/− cells
that were either untreated or HU-treated for 6 or 24 h.
In WT cells, FANCD2 and FANCI were robustly bound
to chromatin and accumulated further during the course
of HU treatment (Figure 3E, lanes 1, 4 and 7). In con-
trast, no chromatin-bound FANCI was detectable in the
D2−/− cells regardless of the presence or absence of HU
(Figure 3E, lanes 2, 5 and 8). Interestingly, a small amount
of residual chromatin-associated FANCD2was detected re-
producibly in untreated or HU-treated I−/− cells (Figure
3E, lanes 3, 6 and 9, red arrows). Since FANCD2 cannot
become monoubiquitinated in I−/− cells (Figure 3B and
C), this finding demonstrates that the non-ubiquitinated
FANCD2 isoform retains chromatin binding ability in the
absence of FANCI. Thus, although FANCD2 and FANCI
are monoubiquitinated in a strictly interdependent man-
ner, they are partially independent of one another regard-
ing their protein stability, nuclear accumulation and chro-
matin recruitment, hinting at separate cellular functions of
the two factors. To further test this, we compared cellular
growth between the WT or WT-like D2−/−:D2 and I−/−:I
cell lines and the I−/−,D2−/− and ID2DKO knockout cells
in a cell proliferation assay. The three knockout cell lines
exhibited significantly reduced cellular growth rates com-
pared to the WT, D2−/−:D2 and I−/−:I cells, indicating that
FANCD2 and FANCI both contribute to cellular prolifer-
ation (Figure 4A). Strikingly, the cellular growth rates of
the three knockout cell lines were also significantly different
from one another, with decreasing colony formation abili-
ties in the following order: I−/− > D2−/− > ID2DKO cells.
These results indicate that FANCD2 and FANCI have par-
tially non-overlapping roles to promote cellular prolifera-
tion in otherwise unperturbed conditions.
FANCD2 and FANCI act in concert during ICL repair
A hallmark of FA is the cellular hypersensitivity to ICL-
inducing agents such as MMC (52), accompanied by a per-
sistent G2/M cell cycle arrest due to a failure to arrest (and
repair) cells at the intra-S-phase checkpoint (1,12,53,54). To
test if FANCD2 and FANCI cooperate to promote cellular
resistance toDNA ICLs, we performed a survival assay. The
cells were plated with increasing concentrations of MMC
and the cell viability was measured after 5 days. D2−/−,
I−/− and ID2 DKO cells were highly and equally sensi-
tive to even the lowest MMC concentration (5 nM) when
compared to the WT cells; moreover the complemented
D2−/−:D2 and I−/−:I cells exhibited WT-like MMC resis-
tance, further indicating full functional complementation
of these cells (Figure 4B). To analyze the cell cycle profiles
of FANCD2- and/or FANCI-deficient cells in unperturbed
and ICL-treated conditions, asynchronous cell populations
were either untreated or treated with 10 nM MMC for 24
h, followed by staining with propidium iodide and FACS
analysis. In untreated conditions, the D2−/−, I−/− and ID2
DKO cells exhibited unaltered cell cycle profiles compared
to the WT cells or their complemented counterparts (Fig-
ure 4C). In contrast,MMC treatment triggered a robust and
comparableG2/Marrest inD2−/−, I−/− and ID2DKOcells
compared toWT,D2−/−:D2 or I−/−:I cells (Figure 4C andD;
Supplementary Figure S2). Thus, FANCD2andFANCI act
in concert to promote cellular resistance to DNA ICLs.
FANCD2 negatively regulates FANCI to promote cellular re-
sistance to APH or HU
FANCD2 and FANCI accumulate on S-phase chromatin
in response to the replication inhibitors APH or HU
(27,49,51,55). Moreover, the Kupfer laboratory recently
demonstrated that FANCD2-deficient patient cells are sen-
sitive to HU treatment (55). To investigate if FANCD2 and
FANCI both contribute to cellular APH or HU resistance,
WT,D2−/−,D2−/−:D2, I−/−, I−/−:I and ID2DKO cells were
plated and either left untreated or treated with increasing
doses of HU (50, 100 or 150 M) or APH (10, 25 or 50
nM). Colony formation of each cell line was determined af-
ter 12 to 14 days. The D2−/− cells exhibited a strikingly in-
creased, dose-dependent hypersensitivity to both HU and
APH compared to WT cells (Figure 5A and B; Supplemen-
tary Figure S3A and B). In contrast, the I−/−cells did not
exhibit any HU or APH hypersensitivity compared to WT
cells, indicating that FANCI is dispensable for the cellular
resistance to HU or APH. Strikingly, the ID2 DKO cells
did not exhibitHUorAPH sensitivity either, demonstrating
that the depletion of FANCI restores the cellular resistance
to these replication stressors in the absence of FANCD2
(Figure 5A and B; Supplementary Figure S3A and B). To
further investigate this, we set out to analyze the cellular
replication stress response inWT,D2−/−, I−/− or ID2DKO
cells in more detail. Since FANCD2 is predicted to protect
stalled replication forks from collapsing into DNA DSBs
(4,22,23), we asked if spontaneous or HU-triggered DNA
DSB levels differed between D2−/− cells and the WT, I−/−
or ID2DKOcells. Cells were untreated or treatedwith doses
of low HU (500 M) or high HU (2 mM) for 24 h and
WCEs were analyzed for the DNA DSB markers  -H2AX
and phospho-RPA2 (replication protein A; phosphorylated
at serines 4 and 8).We did not observe any differences in the
spontaneous or HU-triggered  -H2AX or phospho-RPA2
levels between the four cell lines, indicating that the DNA
DSB burden per se is not elevated in cells lacking FANCD2
and/or FANCI (Figure 5C and D). Next, we asked if the
chromatin recruitment ofHDR repair proteins during repli-
cation stress was differently affected in D2−/− cells com-
pared to WT, I−/− or ID2 DKO cells. CtIP, a key HDR
factor required for replication restart and DNA DSB re-
pair, relies on FANCD2 for its own chromatin recruitment
(24,56,57). To analyze CtIP chromatin binding and CtIP re-
localization into nuclear DNA repair foci, cells were left un-
treated or treated with 2mMHU for 20 h, followed by chro-
matin blotting or immunofluorescence analyses. In support
of our previous findings, CtIP recruitment to chromatin and
into DNA repair foci was severely reduced in untreated and
HU-treated D2−/− cells compared to the WT cells (Fig-
ure 5E and F; Supplementary Figure S4). However, the
I−/− and ID2DKO cells exhibited CtIP recruitment defects
comparable to those observed in the D2−/− cells, suggest-
ing that CtIP recruitment to stalled or collapsed replication
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Figure 4. FANCD2 and FANCI contribute differently to cell proliferation and the cellular response to replication stress. (A) The absence of FANCD2
and FANCI affects cell proliferation synergistically. WT, D2−/−(clones #29 and #39), I−/− (clones #28 and #30) and ID2 DKO (clones #1 to #4) cells,
as well as the complemented counterparts, were plated according to their plating efficiency and total cell counts were performed in triplicate at days 4, 6
and 8. Data points were averaged between clones of identical genetic backgrounds. Error bars represent the standard deviation. (B) FANCD2 and FANCI
act in concert to promote MMC resistance. Cell viability was measured for WT, D2−/−, I−/−, ID2 DKO and complemented cell lines using CellTiter96
Aqueous staining 5 days after the addition of 0, 5, 10 or 15 nM MMC. Results were averaged from a minimum of three replicates and normalized to
the average viability of the respective untreated cells. Error bars represent the standard deviation. (C) FANCD2 and FANCI act in concert to activate
the MMC-triggered intra-S phase checkpoint. WT, D2−/−(clones #29 and #39), I−/− (clones #28 and #30) and ID2 DKO (clones #1 and #2) cells, as
well as the complemented counterparts, were untreated or treated with 10 nM MMC for 20 h, followed by propidium iodide (PI) staining and FACS
analysis. Representative histograms of the cell cycle profiles are shown for each cell line. Blue shading represents G1 phase cells, orange shading represents
S phase cells and grey shading represents G2/M phase cells. (D) Graphic representation of the percentage of the indicated cell populations present in
the G2/M phase of the cell cycle in the absence or presence of MMC. Data points were averaged between clones of identical genetic backgrounds. The
average percentage of the G2/M cell population was determined from a minimum of three replicates. Error bars represent the standard deviation and the
significance was determined by t-test.
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Figure 5. FANCI promotes replication stress-induced cellular apoptosis in the absence of FANCD2. (A) FANCD2, but not FANCI, promotes cellular
resistance to HU. WT, D2−/−(clone #39), I−/- (clone #28) and ID2 DKO (clone #1) cells, as well as the complemented cell lines were plated at low
density and incubated with increasing doses of HU (0–150 M) for 12–14 days to allow for single cell colony formation. Plates were fixed and stained
with Coomassie, and colonies with a minimum of 50 cells were scored. Results were averaged from a minimum of three replicates and normalized to the
respective untreated cells. Error bars represent the standard deviation and significance was determined by t-test. Statistical significance at P < 0.05, P <
0.01 and P < 0.001 are indicated as *, **, ***, respectively. (B) FANCD2, but not FANCI, promotes cellular resistance to APH. WT, D2−/−(clone #39),
I−/− (clone #28) and ID2 DKO (clone #1) cells, as well as the complemented cell lines were plated at low density and incubated with increasing doses
of APH (0–50 nM) for 12–14 days to allow for single cell colony formation. Plates were fixed and stained with Coomassie, and colonies with a minimum
of 50 cells were scored. Results were averaged from a minimum of three replicates and normalized to the respective untreated cells. Error bars represent
the standard deviation and significance was determined by t-test. Statistical significance at P < 0.05, P < 0.01 and P < 0.001 are indicated as *, **, ***,
respectively. (C) FANCD2 and FANCI are dispensable for the prevention of spontaneous or replication stress-induced DNA DSBs. WCE were prepared
from WT (lanes 1 and 5), D2−/− (lanes 2 and 6), I−/− (lanes 3 and 7) and ID2 DKO (lanes 4 and 8) cells that were untreated (lanes 1–4) or treated with
500 M HU for 20 h (lanes 5–8) and analyzed for the induction of pRPA32 (S4/8) and  -H2AX expression by western blot analysis. GAPDH was used
as a loading control. (D) WCE was prepared fromWT (lanes 1 and 5), D2−/− (lanes 2 and 6), I−/− (lanes 3 and 7) and ID2DKO (lanes 4 and 8) cells that
were untreated (lanes 1–4) or treated with 2 mM HU for 20 h (lanes 5–8) and analyzed for DNA DSB markers, pRPA32 (S4/8) and  -H2AX by western
blot analysis. GAPDH was used as a loading control. (E) FANCD2 and FANCI cooperate to recruit CtIP to chromatin in the absence or presence of
replication stress. Chromatin fractions were isolated fromWT,D2−/− (clone #39) and I−/− (clone #28) cells that were untreated (lanes 1–3) or treated with
2 mM HU (lanes 4–9) for the indicated time points and analyzed for the presence of CtIP by western blot analysis. Ku86 was used as a loading control.
(F) FANCD2 and FANCI cooperate to promote CtIP foci formation during replication stress. WT, D2−/− (clone #39), I−/− (clone #28) and ID2 DKO
(clone #1) cells were untreated or treated with 2 mMHU for 20 h and cellular nuclei were analyzed for the presence of CtIP foci. Nuclei with >5 foci were
considered positive for CtIP foci formation. (G) FANCD2 and FANCI are dispensable for RAD51 foci formation during replication stress. WT, D2−/−
(clone #39) and I−/− (clone #28) and ID2 DKO (clone #1) cells were untreated or treated with 2 mM HU for 20 h and cellular nuclei were analyzed for
the presence of RAD51 foci. Nuclei with >5 foci were considered positive for RAD51 foci formation. (H) FANCD2 and FANCI cooperate to promote
the monoubiquitination of chromatin-bound PCNA in the absence or presence of HU-triggered replication stress. Chromatin fractions were isolated from
WT, D2−/− (clone #39), I−/− (clone #28) and ID2 DKO (clone #1) cells that were untreated (lanes 1, 3, 5 and 7) or treated with 2 mM HU (lanes 2, 4, 6
and 8) for 20 h and analyzed for the presence of PCNA and PCNAUb by western blot analysis. H2AX was used as a loading control. (I) FANCD2 prevents
FANCI-dependent cellular apoptosis in unperturbed conditions and following replication stress. WCE were prepared from WT (lanes 1 and 5), D2−/−
(lanes 2 and 6), I−/− (lanes 3 and 7) and ID2 DKO (lanes 4 and 8) cells that were untreated (lanes 1–4) or treated with 100 nM APH for 20 h (lanes 5–8)
and analyzed for phospho-p53 (S15) and p21 by western blot analysis. Ku86 was used as a loading control.
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forks relies on both FANCD2 and FANCI. We next ana-
lyzed the HU-triggered foci recruitment of RAD51, a sec-
ond key HDR protein that forms protein–DNA filaments
and is required for replication fork recovery and HDR re-
pair of DNA DSBs. As expected, WT cells showed sponta-
neous RAD51 foci formation (10% cells), which increased
significantly following 2 mM HU treatment for 20 h (65%
cells). Somewhat unexpectedly, the D2−/−, I−/− and ID2
DKO cells were fully competent for RAD51 foci forma-
tion before and after HU treatment (Figure 5G and Supple-
mentary Figure S5), indicating that neither FANCD2 nor
FANCI are crucial for the relocalization of RAD51 to HU-
induced DNA repair foci. Supportive of this idea, we ob-
served no difference in RAD51 foci formation in the un-
treated or HU-treated FA-D2 patient cell line, PD20, com-
pared to its complemented counterpart, the PD20+D2 cell
line (Supplementary Figure S6).
In addition to its role in DNA repair, FANCD2 has
also been implicated in the so-called DNA damage tol-
erance (DDT) pathway that allows for cellular survival
in the face of persistent DNA damage and replication
stress (58,59). A key activation step of this pathway is
the monoubiquitination of PCNA (proliferating cell nu-
clear antigen), which in turn recruits DNATLS (translesion
synthesis) polymerases to promote continuous, albeit mu-
tagenic, replicative DNA synthesis. Recent studies showed
that HU-induced PCNA monoubiquitination (PCNAUb)
occurs in a FANCD2-supported manner to promote cellu-
lar HU resistance (55,60). To test if PCNAUb formation is
affected differently inD2−/− cells compared to WT, I−/− or
ID2 DKO cells, cells were left untreated or treated with 2
mM HU for 20 h, followed by a chromatin blotting anal-
ysis. As expected, D2−/− cells exhibited a decreased spon-
taneous and HU-induced PCNAUb formation; however, we
observed similarly reduced PCNAUb levels in the I−/− or
ID2 DKO cells (Figure 5H), suggesting that HU-induced
PCNA monoubiquitination relies on both FANCD2 and
FANCI.
Since none of these analyses adequately explained the
unique hypersensitivity of D2−/− cells to HU and APH
we next assessed the status of activated p53 in all of the
cell lines. WT and all three knockout cell lines were un-
treated or treated with APH for 20 h, followed by analysis
of phospho-p53 (S15) and––as a relevant downstream p53
target––cellular p21 protein levels. Strikingly, phospho-p53
and p21 levels were highly elevated in untreated and APH-
treated D2−/− cells, but not in the WT, I−/− or ID2 DKO
cells (Figure 5I). These findings suggest that FANCD2
may protect cells from FANCI-mediated, replication stress-
induced cell death.
FANCD2 promotes the restart of stalled replication forks in-
dependently of FANCI
FANCD2 functions to restart HU or APH-stalled replica-
tion forks, while simultaneously suppressing the firing of
new replication origins (22–25). To test if FANCI shares
these functions, we monitored replication events in WT,
D2−/−, I−/− and ID2 DKO cells with a dual-labeling DNA
fiber assay (22,41). Replication tracts were first labeled with
DigU (red label) for 25 min, then left untreated or treated
with 30 M APH for 6 h to cause replication fork arrest,
followed by a second labeling with BioU (green label) for
40 min (Figure 6A). Different from the efficient fork restart
in WT cells, the proportion of replication forks competent
for restart after APH treatment was severely reduced in
D2−/− cells (45 versus 85%, P < 0.01) (Figure 6B). In par-
allel, the proportion of newly originated replication tracts
(BioU label only) increased significantly (2-fold; P < 0.01)
in D2−/− cells compared to WT cells (Figure 6C). In con-
trast, we observedmuchmilder replication restart defects in
the I−/− cells (63%; P< 0.05) and the ID2DKO cells (54%;
P < 0.01), accompanied by a lower number of newly fired
replication origins (I−/− cells: 1.4-fold, P< 0.05; ID2DKO
cells: 1.6-fold, P < 0.01) compared to the D2−/− cells (Fig-
ure 6B and C). Importantly, the replication restart efficien-
cies were significantly different between the three knockout
cell lines, with an increase in restart efficiency in the order:
D2−/− < ID2 DKO < I−/− cells (Figure 6B). To further
validate these findings in the presence of a second replica-
tion fork stalling agent, HU, we performed a technically im-
proved DNA replication fork restart analysis using DNA
combing (42). Moving replication forks were labeled with
CldU (green label) for 20 min, then left untreated or treated
with 4 mM HU for 4 h to cause replication fork arrest,
followed by a second labeling with IdU (red label) for 40
min (Figure 6D). Comparable to what we observed follow-
ingAPH-mediated fork stalling,WT cells exhibited efficient
fork restart following HU treatment, whereas the propor-
tion of restarted replication forks after HU treatment was
significantly reduced inD2−/− cells (68%, P< 0.01) (Figure
6E). Moreover, we observed milder replication restart de-
fects in the I−/− cells (81%; P < 0.05) and in the ID2 DKO
cells (71%; P < 0.01).
These findings indicate that FANCD2 plays a more cru-
cial role than FANCI during replication fork restart and
the inhibition of new origin firing. Moreover, the fact that
FANCI depletion in D2−/− cells improved these cells’ abil-
ity to restart replication forks and suppress new origin fir-
ing, particularly after APH treatment, provocatively sug-
gests that FANCI may have an inhibitory effect on both
mechanisms in the absence of FANCD2.
Considering that non-ubiquitinated FANCD2 retains
weak chromatin binding activity in I−/− cells (see Fig-
ure 3E), we then hypothesized that the few remaining
chromatin-bound FANCD2 molecules may still be func-
tional and capable of promoting replication fork restart
in the absence of FANCI. If this were indeed the case, it
should be possible to completely alleviate the replication
fork restart defect in I−/− cells by increasing the amount of
chromatin-bound FANCD2. To test this, we overexpressed
FANCD2 in I−/− cells (I−/−:D2o/e, Figure 7A), resulting in
chromatin-bound, non-ubiquitinated FANCD2 levels com-
parable to those observed for chromatin-bound,monoubiq-
uitinated FANCD2 in WT cells, before and after HU treat-
ment (Figure 7B). WT, D2−/− and I−/− cells, as well as
two different I−/−:D2o/e cell clones, were then analyzed for
their replication fork restart efficiencies followingHU treat-
ment using the DNA combing assay. Strikingly, unlike the
I−/− cells that were moderately defective for replication fork
restart (81%,P< 0.05), both I−/−:D2o/e cell cloneswere com-
pletely proficient in restarting HU-stalled replication forks,
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Figure 6. FANCD2 plays a more crucial role than FANCI to promote replication fork recovery. (A) Schematic of the replication fork restart protocol with
representative images of DNA fibers. Red tracks: DigU; green tracks: BioU. (B) FANCD2 plays a more crucial role than FANCI in promoting the restart of
APH-stalled replication forks. The efficiency of replication restart in WT, D2−/− (clone #39), I−/− (clone #28), and ID2DKO (clone #1), as well as in the
complemented cells was measured as the number of restarted replication forks after APH (30 M) mediated fork stalling (DigU-BioU tracts), compared
with the total number of DigU-labeled tracts (DigU plus DigU-BioU). Statistical significance at P < 0.05, P < 0.01 and P < 0.001 are indicated as *,
**, ***, respectively. (C) FANCD2 plays a more crucial role than FANCI in suppressing new origin firing in the presence of stalled replication forks. WT,
D2−/− (clone #39), I−/− (clone #28), and ID2DKO (clone #1), as well as the complemented cells were analyzed for the fraction of newly fired replication
origins during the 40 min post-APH recovery period. Fractions were measured as the number of green-only (BioU) tracts compared with the total number
of spreading replication tracts (BioU plus DigU-BioU). Statistical significance at P< 0.05, P< 0.01 and P< 0.001 are indicated as *, **, ***, respectively.
(D) Schematic of the DNA combing assay with representative images of stretched DNA fibers. Green tracks: CldU; red tracks: IdU. (E) FANCD2 plays
a more crucial role than FANCI in promoting the restart of HU-stalled replication forks. The efficiency of replication restart in WT, D2−/−(clones #29
and #39), I−/− (clones #28 and #30) and ID2DKO (clones #1 and #2) was measured as the number of restarted replication forks after HU-mediated fork
stalling (CldU-IdU tracts), compared with the total number of CldU-labeled tracts (CldU plus CldU-IdU). Data points were averaged between clones of
identical genetic backgrounds. Statistical significance at P < 0.05, P < 0.01 and P < 0.001 are indicated as *, **, ***, respectively.
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Figure 7. Over-expressed FANCD2 fully promotes replication fork restart in the absence of FANCI. (A) Human wild-type FANCD2 can be stably over-
expressed in I−/− cells. A PiggyBac transposon containing the FANCD2 codon-optimized cDNA was introduced into I−/− cells (clone #28), and two
FANCD2-overexpressing I−/− cell lines (named I−/−:D2o/e, clones #2 and #12) were generated. To determine the level of FANCD2 overexpression, WCEs
were prepared fromWT (lanes 1 and 2), I−/− (lanes 3 and 4) and I−/−:D2o/e (lanes 5–8) cells that were untreated (lanes 1, 3, 5, 7) or treated with 4 mMHU
for 4 h (lanes 2, 4, 6 and 8) and analyzed for the presence of FANCD2 by western blot analysis. Actin was used as a loading control. (B) Overexpression of
FANCD2 leads to an increase in FANCD2 chromatin binding in the absence of FANCI. In parallel to the preparation of WCEs described in (A) above,
chromatin fractions were isolated from these same WT (lanes 1 and 2), I−/− (lanes 3 and 4) and I−/−:D2o/e (lanes 5–8) cells that were untreated (lanes
1, 3, 5, 7) or treated with 4 mM HU for 4 h (lanes 2, 4, 6 and 8) and analyzed for the presence of FANCD2 by western blot analysis. H3 was used as
a loading control. (C) FANCD2 overexpression rescues the replication fork restart defects in FANCI null cells. The efficiency of replication fork restart
in WT, D2−/−, I−/− and I−/−:D2o/e cells was measured as the number of restarted replication forks after HU-mediated fork stalling (CldU-IdU tracts),
compared with the total number of CldU-labeled tracts (CldU plus CldU-IdU). Statistical significance at P < 0.05, P < 0.01 and P < 0.001 are indicated
as *, **, ***, respectively.
comparable to the WT cells (Figure 7C). These results in-
dicate that non-ubiquitinated, chromatin-bound FANCD2
is fully competent to promote replication fork restart in the
absence of FANCI.
Stabilizing RAD51 nucleoprotein filaments restores HDR-
mediated DNA DSB repair in cells lacking functional
FANCD2
Cells can utilize HDR to repair DNA DSBs (5,61), includ-
ing those created by the unhooking of a DNA ICL le-
sion (9,10). In addition, a growing number of HDR factors
have been implicated in promoting replication fork recov-
ery in concert with FANCD2 (4,22–26,62), suggesting that
the restart machinery utilizes HDR-related mechanisms to
restart DNA synthesis at a stalled fork. To investigate the
roles of FANCD2 and FANCI in HR-mediated DNADSB
repair we utilized a well-established reporter plasmid DNA
repair assay (36). In this assay, a plasmid containing two
non-functioning GFP genes in tandem is transfected into
the cells. One non-functioningGFP gene contains an I-SceI
restriction enzyme recognition site and the other is trun-
cated at both the 5′- and 3′-ends. Digestion of the plas-
mid with I-SceI creates a DNA DSB in the non-functional
GFP gene that can subsequently use the truncated GFP
gene as template to restore GFP expression by homology-
directed gene conversion repair. As a control for this assay,
we included the RAD54B−/−/− HCT116 cell line that has
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Figure 8. FANCD2 plays a crucial role to promote HDR-mediated,
RAD51-dependent DNA DSB repair. (A) A GFP-HDR DNA repair as-
say was used to determine the HDR efficiency in WT, D2−/−(clones #29
and #39), I−/− (clones #28 and #30) and ID2 DKO (clones #1 and #2),
as well as in the complemented cells. RAD54B−/−/− cells were included
in the assay as a control cell line that is severely HDR deficient. In this as-
say, I-SceI restriction enzyme digestion creates a DSB in the HDR reporter
plasmid (DR-GFP). Repair of the DSB by HDR restores GFP expression.
The repair efficiency was determined by dual GFP and mCherry positive
cells divided by the mCherry positive cells (transfection control). Results
were averaged from a minimum of three replicates and normalized to the
average repair efficiency in the WT cells. Data points were averaged be-
tween clones of identical genetic backgrounds. Statistical significance at P
< 0.05, P < 0.01, P < 0.001 and P < 0.0001 are indicated as *, **, ***,
**** respectively. (B) The HDR assay shown in (A) was repeated for the
WT, D2−/−, I−/− and ID2 DKO cells in the absence or presence of the
RAD51 stabilizer, RS-1 (7.5 mM). Results were averaged from aminimum
of three replicates and normalized to the average repair efficiency in the
WT cells. Statistical significance at P< 0.05, P< 0.01, P< 0.001 and P<
0.0001 are indicated as *, **, ***, **** respectively.
an established HDR defect (63,64). The D2−/− cells were
severely deficient in HDR-mediatedDNADSB repair (34%
of WT), a level that was comparable to the RAD54B−/−/−
cells (Figure 8A). In contrast, the I−/− and ID2 DKO cells
exhibited much milder HDR repair defects (62 and 56% of
WT, respectively (Figure 8A)). These results indicate that (i)
FANCD2 has a more important role than FANCI in HDR-
mediated DNA DSB repair and––surprisingly that––(ii)
FANCI opposes HDR-mediated DNA DSB repair in the
absence of FANCD2.
FANCD2 was proposed to recruit the HDR factor
RAD51 to chromatin during replication stress and to sta-
bilize RAD51 nucleoprotein filaments that are crucial to
promote HDR mechanisms of replication fork recovery
and DSB repair (4,65). Thus, we wanted to ask if the
HDR repair deficiency observed in cells lacking functional
FANCD2 can be overcome by stabilizing RAD51 filament
formation. To this end, we repeated theGFPHDRassay de-
scribed above in WT, D2−/− I−/− and ID2DKO cells in the
absence or presence of a RAD51 filament stabilizing agent,
RS-1 (66). In the presence of RS-1, all three knockout cell
lines restored their HDR repair efficiency to a level com-
parable to the untreated WT cells (Figure 8B). Taken to-
gether, these findings support a current model (65) in which
chromatin-bound FANCD2 plays a crucial role in stabi-
lizing RAD51 filament formation during HDR-mediated
DNA repair and, consequently, replication fork recovery.
DISCUSSION
In this study, we analyzed the functions of FANCD2 and
FANCI during DNA replication, using isogenic knockout
cell lines. Our results suggest that FANCD2 and FANCI
fulfill partially independent and at times opposing roles in
the cellular replication stress response (Figure 9).
A novel cell model to study common and independent roles of
FANCD2 and FANCI
Our model system provides unique advantages compared
to the use of FA patient cells or siRNA knockdown
approaches. First, patient-derived FA-D2 and FA-I cell
lines are derived from different genetic backgrounds and
exhibit residual FANCD2 and FANCI protein expres-
sion (12,43,44); second, siRNA-mediated knockdown ap-
proaches cannot completely or permanently eliminate pro-
tein expression (12,24,25,44). In contrast, our system al-
lowed for a functional dissection of the roles of FANCD2
and FANCI in identical genetic background settings and in
the complete absence of any FANCD2 and/or FANCI pro-
tein expression. On a technical note, but similar to previ-
ous reports (45,47), our attempts to complement I−/− cells
with a stably integrated FANCI cDNA were unsuccessful
due to the rapid loss of FANCI expression, strongly sug-
gesting that cells may not tolerate FANCI expression from
a random genomic locus or, more likely, that FANCI over-
expression is toxic (see also below).
Based on the fact that all known FA-D2 or FA-I patient
cell lines have residual FANCD2 and FANCI (respective)
expression (12,43,44), we predicted that the complete loss
of one or both proteins may be lethal. However, the D2−/−,
I−/− and ID2DKO cell lines were viable, indicating that nei-
ther FANCD2 nor FANCI are essential in human somatic
cells; needless to say, however, these experiments do not rule
out important developmental roles for either of these genes,
a likelihood that is consistent with the developmental ab-
normalities often observed in FA patients. While not for-
mally essential, both proteins contribute to cellular prolif-
eration. Importantly, the fact that ID2 DKO cells prolifer-
ated significantly slower than either of the singly-null cells
demonstrates that FANCD2andFANCI have (at least) par-
tially non-overlapping roles during normal cellular prolif-
eration. Consistent with this idea, in the Xenopus system
the ID2 dimer dissociates upon activation in S-phase, fol-
lowed by consecutive recruitment of FANCD2 and FANCI
to S-phase chromatin (27). Furthermore, FANCD2 acts in-
dependently of FANCI to assemble and recruit the BLM
helicase complex to replicating chromatin (22).
A separation-of-function between FANCD2 and FANCI
is further supported by our finding that ∼40 to 50% of ei-
Downloaded from https://academic.oup.com/nar/article-abstract/45/20/11837/4559113
by Ulsan Natl Inst of Science & Technology user
on 29 January 2018
Nucleic Acids Research, 2017, Vol. 45, No. 20 11853
Figure 9. Model of common and independent functions of FANCD2 and FANCI. (A) FANCD2 and FANCI act in concert during the cellular response
to DNA ICLs in S-phase to promote ICL removal and cell survival. (B and C) FANCD2 and FANCI have separate roles during the cellular response to
APH- or HU- stalled replication forks. (B) FANCD2––but not FANCI––is crucial to recruit RAD51 and promotes RAD51 filament formation to mediate
fork recovery. (C) Simultaneously, FANCD2 promotes cell survival by inhibiting a FANCI-dependent lethal response.
ther protein is stably expressed in absence of the respec-
tive other partner, in agreement with some previous studies
(12,44,48). Interestingly, nuclear accumulation of FANCD2
and FANCI occurred independently of one another in un-
perturbed conditions. This suggests that FANCD2 and
FANCI are not interdependent for their nuclear localiza-
tion per se: in unperturbed conditions, cells simply upreg-
ulate the nuclear import of residual FANCI in absence of
FANCD2 and vice versa, possibly in an attempt to par-
tially compensate for one another. During replication stress
however, the reduced FANCI and FANCD2 protein levels
in I−/− and D2−/− cells, respectively, become limiting and
block sufficient nuclear FANCD2 and FANCI accumula-
tion. Inconsistent with this interpretation, it has been re-
ported that the FA-D2 patient cell line, PD20, lacks any
nuclear FANCI protein compared to the complemented
PD20+D2 cells (50). We suggest that this discrepancy may
be because the difference in FANCI protein expression
appears to be greater between the PD20 cells and the
highly FANCD2-overexpressing PD20+D2 cells (12) than
between our D2−/− and D2−/−:D2 cells.
Different roles for chromatin-bound and non-chromatin-
bound FANCD2 and FANCI?
Importantly, the independent nuclear accumulation of
FANCD2 and FANCI was not mirrored by their chro-
matin binding behavior, since both proteins appeared to be
strongly interdependent for chromatin recruitment even in
unperturbed conditions. Considering that the three knock-
out cell lines have significantly different growth rates,
the chromatin binding ability of FANCD2 and FANCI
is not indicative of a cell’s proliferation ability. This in
turn suggests that FANCD2 and FANCI have functions
that do not require a direct association with chromatin
and supports accumulating evidence that FANCD2 and
FANCI have independent roles, such as the (only FANCI-
mediated) stabilization of the FA core complex on chro-
matin or the (only FANCD2-mediated) support of A-
NHEJ DNA repair mechanisms (see also Supplementary
Figure S7) (22,25,27,47,55,62,67). Our observation that
non-ubiquitinated FANCD2 is present on chromatin in the
absence of FANCI is in agreement with our previous find-
ings that non-ubiquitinated FANCD2 binds chromatin in
FANCI-depleted Xenopus extracts (22,27) and supports a
recent study that showed that FANCD2 binds DNA prior
to beingmonoubiquitinated (68).Moreover, we have shown
that low levels of non-ubiquitinated FANCD2 accumulate
on chromatin in an APH-inducible manner to promote
replication fork restart, regardless of the presence or ab-
sence of a functional FA core complex (25). Finally, this
current study shows that I−/− cells that have residual levels
of chromatin-bound, non-ubiquitinated FANCD2 are still
capable of partially supporting replication fork restart fol-
lowing APH or HU treatment; moreover, simply increasing
the chromatin-boundFANCD2 levels via FANCD2overex-
pression completely alleviated the replication restart defects
in these cells. In toto, these observations argue strongly that
the non-ubiquitinated FANCD2 isoform is functional in its
chromatin-bound state.
Importantly, however, the residual FANCD2 chromatin
binding in FANCI-deficient cells did not alleviate their
ICL sensitivity, reinforcing the model of a linear FA ICL
repair pathway, where the FANCI-dependent FANCD2
monoubiquitination is crucial for cellular ICL resistance
(12,14,44,69) (Figure 8A). Thus, these experiments define a
separation-of-function for FANCD2 monoubiquitination:
it is required for ICL repair but dispensable for replication
fork restart.
The striking finding that onlyD2−/− cells –– but not I−/−
or ID2 DKO cells––were sensitive to HU or APH and ex-
hibited elevated activation of phospho-p53 and p21 expres-
sion is supported by a recent report showing HU sensitivity
in FA-D2 patient cells (55). Together, these studies suggest
that FANCD2may prevent FANCI-mediated cell death fol-
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lowing replication stress (Figure 9). Since D2−/− cells are
indistinguishable from I−/− or ID2 DKO cells regarding
their spontaneous or stress-induced DNA DSB accumula-
tion, and the recruitment of HDR repair factors or the ac-
tivation of the DDT pathway, FANCD2’s role in prevent-
ing APH- or HU-triggered cell death appears to be separate
from its role in protecting chromosomal stability.Moreover,
since I−/− and ID2DKO cells are equally resistant toHUor
APH despite harboring different residual chromatin-bound
FANCD2 levels, FANCD2’s role in preventing APH/HU-
induced cell death may in fact not depend on its own chro-
matin association. Consistent with our findings and in-
terpretation, a role for FANCD2 in preventing apoptosis
and cell death was also suggested by several groups (70–
72). Moreover, a recent study showed that siRNA-mediated
knockdown of FANCI, but not FANCD2, substantially re-
duced cellular apoptosis after UV treatment (67). Clearly,
in the future, the mechanistic basis of FANCD2′s putative
role in cell death induction will be a key question for the
field to answer (Figure 9).
Opposing roles for FANCD2 and FANCI during HDR-
mediatedmechanisms of fork recovery andDNADSB repair?
In agreement with our previous findings (22–24), FANCD2
promoted the restart of APH-stalled replication forks, a
process that requires several members of the HDR repair
machinery, including RAD51 (22,24,25,41,73). The fact
that the HDR repair defect in D2−/− cells could be al-
most completely rescued by stabilizing RAD51 filaments
via RS-1 supports a model in which FANCD2 functions to
(i) promote replication fork restart and (ii) protect nascent
DNA from nucleolytic degradation (4,22–24) by promoting
RAD51 filament formation. In support of this model, a re-
cent study showed that the FANCD2:FANCI heterodimer
stabilizes RAD51 filament formation in vitro (65). It should
be noted that wild-type-like RAD51 foci formation was ob-
served in all three knockout cell lines including the D2−/−
cells (Figure 5G), seemingly contradicting the idea that
FANCD2 is required for RAD51 filament formation. How-
ever, findings from our laboratory and others (24,73) in-
dicate that foci formation of HDR repair factors, such as
RAD51 or CtIP, does not occur at intact stalled replica-
tion forks, but instead occurs much later once the forks have
collapsed. The question, therefore, of whether RAD51 foci
can form in the absence of FANCD2 remains controversial
(65,74–78).
The I−/− cells exhibited milder defects in HDR-mediated
replication restart and DSB repair than theD2−/− cells, ini-
tially suggesting separate roles for FANCD2 and FANCI
during HDR as well. However, two additional findings
suggest otherwise: first, overexpression of FANCD2 com-
pletely rescued HDR-mediated replication restart defects
in I−/− cells. Second, ID2 DKO cells exhibited a less pro-
nounced HDR defect than the D2−/− cells. Thus, FANCI’s
role in HDR may be to simply stabilize FANCD2, which
by itself is the actual recruiter of HDR factors. In this
scenario, the residual chromatin-bound, non-ubiquitinated
FANCD2 would allow I−/- cells to partially support
HDR-mediated fork restart, similar to chromatin-bound
FANCD2 in FA core complex-deficient cells (25). Impor-
tantly, FANCD2- and FANCI-deficient cells can compen-
sate for their replication restart defects by the enhanced fir-
ing of new replication origins (22,41), which likely coun-
teracts chromosomal instability in the presence of repli-
cation stress. Our finding that cells lacking FANCI mod-
estly upregulate new origin firing during replication stress
seemingly contradicts a recent study showing that FANCI
is required for new origin firing during replication stress
(62). However, these authors investigated the role of FANCI
mostly under continuous low replication stress conditions
(0.2 mMHU), whereas our study used transient, high repli-
cation stress conditions (30 M APH for 6 h), indicating,
at the very least, that FANCI is not required for new origin
firing when replication forks are stalled for several hours.
Perhaps the most unexpected finding was that cells lack-
ing both FANCD2 and FANCI exhibited intermediate
HDRrepair and replication fork restart defects,more severe
than FANCI-deficient cells, but less severe than FANCD2-
deficient cells.We suggest at least two possible explanations:
(i) FANCI actively opposes FANCD2 to negatively regu-
late HDR or (ii) FANCD2 and FANCI work in concert
during HDR, but FANCI becomes inhibitory to HDR in
the absence of FANCD2 (Figure 9). FANCD2 and FANCI
can form a protein complex with RAD51 and contribute to
RAD51 recruitment to DNA (65). If FANCI is in fact the
direct interactor with RAD51 in vivo, the nuclear (but not
chromatin-bound) FANCI may actively sequester RAD51
away from the DNA in FANCD2-deficient cells, causing the
particularly severe HDR phenotype observed in these cells.
Importantly, in both of these scenarios it would be predicted
that the overexpression of FANCI would be deleterious for
HDR (and presumably, therefore, cell viability), which was
indeed observed by us and others in our inability to estab-
lish FANCI-overexpressing complemented clones. Last, it
may also be possible that only in the absence of both pro-
teins is a compensatory/back-up pathway engaged that can
facilitate RAD51 recruitment.
In summary, our findings suggest a model in which
FANCD2 and FANCI have partially non-overlapping roles
in promoting cell survival and HR-mediated fork recovery
in the presence of APH or HU-induced replication stress.
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